Treatment satisfaction with Ra-223 in Japan
This study aims to answer the research question: Are Japanese bone metastatic CRPC patients satisfied with their Ra-223 treatment, and what factors drive such satisfaction? It also aims to determine patient anxiety regarding prostate cancer while on treatment with Ra-223, and assess the effect on quality of life.
-Age ≥20 years old (age of maturity in Japan) -Male, diagnosed with CRPC -With ≥2 bone metastases and no visceral metastasis based on the most recent imaging procedure -Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 0-1, not in end-stage palliative care -Designated by examining physician to undergo Ra-223 treatment either in the 1st, 2nd, or 3rd line of CRPC therapy -Has provided written, informed consent (in Japanese) -Has ≥6 months life expectancy
- Participation in an investigational program with interventions outside of routine clinical practice - Currently receiving any chemotherapy for CRPC or any new hormone therapy (enzalutamide, abiraterone acetate) at enrolment - Where any of the below conditions apply: -- Started or switched to new androgen deprivation therapy (ADT) (e.g., LHRH agonists and antagonists, anti-androgens, estrogens,) within 4 weeks prior to enrolment or planning to start new treatment prior to 1st Ra-223 injection -- Treatment with anticancer-chemotherapy within previous 4 weeks, or planned before the 1st Ra-223 injection, or failure to recover from adverse events (AEs) (CTCAE Grade >2) due to anticancer chemotherapy administered more than 4 weeks prior -- Systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within the previous 24 weeks -- Previous hemi-body external radiotherapy - Imminent or established spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI) - Presence of other maligancy at enrolment - Otherwise deemed incapable of participating by examining physician
Many Locations, Japan
E-mail: [email protected]
Phone: (+) 1-888-8422937
Treatment Satisfaction with Ra-223 among Japanese Castration Resistant Prostate Cancer (CRPC) Patients